Covalon Technologies Ltd Stock Price, News & Analysis

Covalon Technologies Ltd. (CVALF) announced the resignation of its CFO, Danny Brannagan, effective January 2022. The company plans to appoint an interim CFO while searching for a permanent successor with strong financial leadership skills. CEO Brian Pedlar expressed gratitude for Brannagan's contributions. Covalon specializes in developing patent-protected medical products aimed at enhancing patient outcomes in areas like wound care and infection management. The company is listed on the TSX Venture Exchange and OTCQX, symbol CVALF.

Covalon Technologies Ltd. reported a net profit of $23.5 million or $0.91 per share for fiscal 2021, largely due to income from the sale of AquaGuard operations. Revenue from continuing operations surged 45% to $19.6 million, driven by a significant increase in product sales.

The fourth quarter net income was $1.0 million or $0.04 per share. Covalon ended the year with $25.5 million in cash and no debt. The company achieved a gross margin of 50%, improved from 34% in the prior year, indicating strong operational performance.

Covalon Technologies Ltd. (CVALF) will report its Q4 and year-end Fiscal 2021 financial results on December 13, 2021, before markets open. A conference call is scheduled for the same day at 9:00 am EST, allowing stakeholders to discuss these results. Participants can join by calling the provided numbers. Covalon specializes in advanced medical technologies and offers patent-protected medical products aimed at improving patient outcomes in wound care and surgical procedures. Detailed financial documents will be available on SEDAR and through Covalon's website.

Covalon Technologies Ltd. (OTCQX:CVALF) will present at the SNN Network Canada Virtual Event 2021 on December 8, 2021, at 3:30 PM EST. CEO Brian Pedlar will host the presentation and answer investor questions. Recently debt-free, Covalon has over $24 million in cash, approximately $0.93 per share, and is poised for growth in its biological and antimicrobial product lines. Interested investors can register for 1-on-1 meetings and access the live presentation via the event link provided.

Covalon Technologies Ltd. announces the retirement of Dr. Myrna Francis from its Board of Directors, effective September 24, 2021, due to new professional commitments. Amir Boloor, Chair of the Board, praised her significant contributions and healthcare expertise that have benefitted the company's medical products business. President and CEO Brian Pedlar also expressed gratitude for her service over the past three years. Covalon is involved in developing and marketing patent-protected medical products aimed at improving patient outcomes in advanced wound care and infection management.

Covalon Technologies Ltd. announced the voting results from its Fiscal 2020 Annual and Special Meeting of Shareholders held on June 30, 2021. Shareholders approved all items, including the election of the Board of Directors, the appointment of auditors, and the amended stock option plan. A total of 11,030,811 shares, representing 42.72% of the company's shares, were voted. Notably, Amir Boloor and Ron Smith received 99.965% shareholder approval. The results will be filed on SEDAR, and further details are available in the management information circular dated May 26, 2021.

Covalon Technologies Ltd. (CVALF) is set to release its Q2 Fiscal 2021 financial results on May 31, 2021, before market opening. A conference call will follow at 9:00 AM EST for discussion. Participants can join via toll-free numbers in North America or local Toronto lines. Financial statements will be available on SEDAR and Covalon's website. Covalon specializes in patent-protected medical products aimed at improving patient outcomes across advanced wound care, infection management, and surgical procedures.

Covalon Technologies Ltd. (CVALF) will announce its fiscal 2021 Q1 financial results on March 1, 2021, before market opening. A conference call is scheduled for the same day at 9:00 AM EST, allowing stakeholders to discuss these results. Interested parties can participate via local and toll-free numbers provided in the release. Financial statements will be available on SEDAR and the company’s website. Covalon specializes in medical products aimed at improving patient outcomes in advanced wound care, infection management, and surgical procedures.

Covalon Technologies Ltd. (CVALF) is set to release its Fiscal 2020 Third Quarter financial results on August 24, 2020, prior to market opening. A conference call will be conducted at 9:00am EST on the same day to discuss these results. Investors can access the call via local and toll-free numbers provided. The results and related materials will be available on SEDAR and Covalon's investor relations site.